Acrivon Therapeutics
About Acrivon Therapeutics
Acrivon is a clinical stage oncology company leveraging our unique precision medicine platform, called Acrivon Predictive Precision Proteomics (AP3), for development of our drug pipeline. AP3 is used to generate proprietary OncoSignature® companion diagnostics to identify the patients who will benefit from our medicines.
The name Acrivon (derived from Greek for “accurate”) embodies how our OncoSignature® tests link the patient’s active tumor-driving mechanisms with the drug’s mode-of-action to accurately match our therapies with patients who will benefit independent of underlying genetic tumor alterations. Our pipeline includes the advanced Phase 2 lead program, ACR-368 (prexasertib), a clinically active CHK1/2 inhibitor, as well as preclinical programs targeting critical nodes in DNA Damage Response (DDR) and cell cycle regulation.
Acrivon’s team is a rare blend of leading scientific pioneers and highly accomplished executives. The team is located at two Centers of Excellence in Boston and Lund/Copenhagen in Scandinavia leveraging regional expertise, infrastructure, and capabilities.
In addition to learning from some of the field’s greatest minds, our committed team members are encouraged to realize their full potential in work and life. We’re a passionate group that values openness, creativity, fresh perspectives, transformative ideas, and a positive can-do attitude. We value diversity, integrity, and passion for scientific excellence, and care deeply about our patients.
If you have the drive and passion to build the future with us, please see our current open positions.
5 articles about Acrivon Therapeutics
-
Acrivon Therapeutics Announces the Appointment of Adam Levy, Ph.D., M.B.A., Experienced Biotech Investor Relations and Strategy Executive, to Senior Vice President and Head, Investor Relations and Corporate Affairs
7/25/2023
Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV) today announced that Adam D. Levy, Ph.D., M.B.A., has joined Acrivon as senior vice president and head, investor relations and corporate affairs.
-
Acrivon Therapeutics Announces the Appointment of Seasoned Biopharma Executive Charles Baum, M.D., Ph.D., a Recognized Leader in Clinical Precision Oncology, to its Board of Directors
6/22/2023
Acrivon Therapeutics, Inc. today announced that Charles (Chuck) Baum, M.D., Ph.D., founder, president, head of research and development, board member, and former chief executive officer of Mirati Therapeutics, has been appointed to Acrivon’s board of directors.
-
Acrivon Therapeutics announced the pricing of its initial public offering Tuesday, putting all of its 7,550,000 shares of common stock up for sale for $12.50 apiece.
-
Akoya Biosciences to Partner with Acrivon Therapeutics for the Clinical Development of Acrivon’s Proprietary OncoSignature® Test into a Companion Diagnostic
6/28/2022
The OncoSignature ® test developed based on Acrivon’s AP3 platform is a first-of-its-kind spatial signature assay to identify patients most likely to respond to ACR-368, an advanced Phase 2 targeted oncology agent for solid cancers.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.